Potential health impacts and lung microbiome changes among smoking and smokeless tobacco use : A technical scan

• Main Authors: Manikandan Sathiyaseelan, Krishnan Srinivasan, Jeneth Berlin Raj, Pajanivel Ranganadin, Balanehru Subramanian
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2021-01-01
• Series: Eurasian Journal of Pulmonology
• Subjects: bacterial growth; inflammatory changes; tobacco users
• Online Access: http://www.eurasianjpulmonol.com/article.asp?issn=2148-5402;year=2021;volume=23;issue=2;spage=77;epage=82;aulast=Sathiyaseelan

Globally, 1.3 billion peoples use tobacco products daily, most of them from low- and middle-income countries. Every year, 8 million of the population died because of the usage of tobacco, as per the WHO report. Tobacco-related diseases, likely lung cancer, emphysema chronic obstructive pulmonary disease, and chronic respiratory diseases, are more common. Nicotine is a highly addictive chemical found in the tobacco plant and also in all other tobacco products. All tobacco products contain nicotine that causes the release of dopamine in the pleasure and motivation areas of the brain. Both smoking and smokeless tobacco products contain many harmful chemicals that affect the lung mucociliary clearance and also inactivate the immune system and lead to increases in the risk of infection and the development of deleterious bacterial growth in the lungs. In the lung microbiome, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa bacterial species were found to a higher level in smoking tobacco users as that may increase morbidity and mortality. The lung microbiome changes taking place in the lung due to smokeless tobacco usage are less documented so far. In future research, microbiome studies help to understand disease pathogenesis.